Manufacturing facilities
Klio’s is forging on business collaborations and strengthening R&D,
as the manufacturing facility will be operational by Q3 FY23.
Business Collaboration is one of the key verticals of KLIO. A robust networking relationship will be developed with API and Intermediate Manufacturers, R&D providers by leveraging on the strengths of network partners to forge mutually beneficial business opportunity.
By leveraging on the combined strengths of the network, Klio Pharma Private Limited will significantly reduce the time to market the products from its new manufacturing facility by the time the manufacturing plant is ready to commence production.
| Manufacturing Facilities | Location | GMP Status | Activity |
| Lee Pharma Ltd | Hyderabad | FDA Approved | Metaxalone is making headway for US Market |
| Chemeca Drugs | Vizag | FDA Approved | Eltrombopag, Voriconazole validations planned in February/March… (year) |
| Trimax Biosciences | Raichur | FDA Approved | Validations completed for Ritonavir and Propafenone. |
| Radison Labs | Humnabad | WHO GMP | |
| Sridhara Laboratories | Hyderabad | Contract Manufacturing |
- Reactor Capacities ranging from 0.05 Kl to 15 Kl with mix of GLRs and SSRs
- Dedicated Hydrogenation and high pressure reaction block
- Dedicated Pilot and Small volume block
- Isolated reactors for Bromination, Chlorination and other acidic reactions
- Infrastructure to handle reaction temperatures of -20 to 200 C
- Zero Liquid Discharge for Effluent treatment
- Solvent Recovery System
- Enterprise Resource Planning tool (ERP) for operations
- Project Management tool to track progress of R&D Projects
- IT tools to strengthen quality and regulatory compliance